<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01962363</url>
  </required_header>
  <id_info>
    <org_study_id>EPI-743 PM</org_study_id>
    <nct_id>NCT01962363</nct_id>
  </id_info>
  <brief_title>EPI-743 in Friedreich's Ataxia Point Mutations</brief_title>
  <official_title>A Phase 2A Clinical Trial of EPI-743 (Vincerinoneâ„¢) on Visual Function in Friedreich's Ataxia Patients With Point Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of South Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Edison Pharmaceuticals Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Friedreich's Ataxia Research Alliance</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of South Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of EPI-743 in patients with Friedreich's&#xD;
      Ataxia point mutations&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to investigate whether treatment with EPI-743 has a&#xD;
      discernible impact on visual function-including visual acuity, visual fields and color vision&#xD;
      as well as on any of a number of functional and subject/clinician-rated scales relevant in&#xD;
      the treatment of Friedreich's ataxia, and to determine the safety of treatment with EPI-743.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual function</measure>
    <time_frame>3 months</time_frame>
    <description>Low contrast acuity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety parameters</measure>
    <time_frame>3 months</time_frame>
    <description>Clinical and laboratory safety parameters</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual function</measure>
    <time_frame>3 months</time_frame>
    <description>Visual fields as assessed by Humphrey 30-2 exam; High contrast visual acuity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurologic function</measure>
    <time_frame>3 months</time_frame>
    <description>Friedreich's Ataxia Rating Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical function</measure>
    <time_frame>3 months</time_frame>
    <description>25-foot walk (for subjects capable of completing the test on enrollment);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life</measure>
    <time_frame>3 months</time_frame>
    <description>Patient report via rating scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activities of Daily Living</measure>
    <time_frame>3 months</time_frame>
    <description>Patient report via rating scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac indices</measure>
    <time_frame>3 months</time_frame>
    <description>Echocardiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Upper extremity function</measure>
    <time_frame>3 months</time_frame>
    <description>9 hole peg test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease biomarkers</measure>
    <time_frame>3 months</time_frame>
    <description>Glutathione cycle components</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Friedreich's Ataxia</condition>
  <arm_group>
    <arm_group_label>EPI-743</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EPI-743, oral, 400mg three times daily for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EPI-743</intervention_name>
    <description>EPI-743 (alpha-tocotrienol quinone) is a small molecule therapeutic that was rationally designed to replete reduced glutathione through NQO1-catalyzed electron transfer from NADPH.</description>
    <arm_group_label>EPI-743</arm_group_label>
    <other_name>Vincerinone, alpha-tocotrienol quinone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of genetically confirmed Friedreich's ataxia point mutation.&#xD;
&#xD;
          2. Visual acuity at baseline more than 15 letters on high contrast EDTRS at four meters.&#xD;
&#xD;
          3. FARS score of 20 to 90.&#xD;
&#xD;
          4. Male or female between 18 and 65 years of age.&#xD;
&#xD;
          5. Agreement to use contraception if within reproductive years&#xD;
&#xD;
          6. Hormone replacement therapy, if used, must remain stable for the duration of the&#xD;
             study.&#xD;
&#xD;
          7. Willingness and ability to comply with study procedures.&#xD;
&#xD;
          8. Willingness and ability to arrive at study site metropolitan area day prior to&#xD;
             evaluations.&#xD;
&#xD;
          9. Abstention from use of dietary supplements and non-prescribed medications at least 30&#xD;
             days prior to initiation of treatment and for the duration of the study. This would&#xD;
             specifically include idebenone, Coenzyme Q10 and vitamin E.&#xD;
&#xD;
         10. Abstention from foods or beverages or bars fortified with Coenzyme Q10, vitamin E,&#xD;
             super fortified functional foods or beverages at least 30 days prior to initiation of&#xD;
             treatment and for the duration of the study.&#xD;
&#xD;
         11. Abstention from use of other investigative or non-approved drugs within 30 days of&#xD;
             enrollment and for the duration of the study.&#xD;
&#xD;
         12. Subject can swallow multiple size 0 capsules.&#xD;
&#xD;
         13. Subject has voluntarily signed an IRB approved informed consent form to participate in&#xD;
             the study after all relevant aspects of the study have been explained and discussed&#xD;
             with the subject.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Allergy to EPI-743 or sesame oil or nuts.&#xD;
&#xD;
          2. Clinically significant bleeding condition or abnormal PT/PTT INR (INR &gt; two; PTT &gt;&#xD;
             two-times normal).&#xD;
&#xD;
          3. Liver insufficiency with LFTs greater than three-times upper normal limit at&#xD;
             screening.&#xD;
&#xD;
          4. Renal insufficiency with creatinine &gt; 1.5 at screening.&#xD;
&#xD;
          5. Fat malabsorption syndromes.&#xD;
&#xD;
          6. Any other respiratory chain diseases of the mitochondria or inborn errors of&#xD;
             metabolism.&#xD;
&#xD;
          7. Any other ophthalmologic conditions.&#xD;
&#xD;
          8. Clinically significant cardiomyopathy with ejection fraction &lt; 40 percent at&#xD;
             screening.&#xD;
&#xD;
          9. Clinically significant arrhythmia within past two years requiring treatment.&#xD;
&#xD;
         10. Surgery planned through the duration of the study, including follow-up.&#xD;
&#xD;
         11. Pregnancy or breastfeeding.&#xD;
&#xD;
         12. Anticoagulant therapy within 30 days of enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Theresa A Zesiewicz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of South Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>October 10, 2013</study_first_submitted>
  <study_first_submitted_qc>October 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2013</study_first_posted>
  <last_update_submitted>June 28, 2016</last_update_submitted>
  <last_update_submitted_qc>June 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Friedreich's ataxia point mutation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
    <mesh_term>Friedreich Ataxia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>Tocotrienol, alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

